Continuous nasal administration of antigen is critical to maintain tolerance in adoptively transferred autoimmune arthritis in SCID mice
- 5 August 2002
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 129 (2) , 224-231
- https://doi.org/10.1046/j.1365-2249.2002.01903.x
Abstract
SUMMARY: Mucosal tolerance is a natural mechanism that prevents immunological reactions to antigens by altering the activity of immune cells of pathogenic clones without modulating the entire immune system. This ‘natural immune suppression’ can be exploited when antigen(s) of the target organ in an autoimmune disease is used for mucosal treatment. Being inspired by the experimental results in animal models, clinical trials using type II collagen for mucosal treatment have been conducted in rheumatoid arthritis. High-density proteoglycan (aggrecan) is another major macromolecular component in articular cartilage, and may be a candidate autoantigen for provoking immune reactions in patients with rheumatoid arthritis. Indeed, like type II collagen, systemic immunization of genetically susceptible mice with proteoglycan (PG) aggrecan induces progressive autoimmune polyarthritis. Here, we investigated whether intranasally applied PG can be effective in suppressing PG-induced arthritis (PGIA) in BALB/c mice. We found that nasal administration of 100μg PG exerted a strong suppressive effect on both the incidence and severity of the disease, most probably by reducing responsiveness towards the immunizing PG antigen. When we transferred PGIA into genetically matched but immunodeficient SCID mice, we were able to establish a tolerized state, but only if the recipient SCID mice received lymphocytes from tolerized animals and intranasal treatment with PG was continued. Without nasally administered antigen, the transferred anergic cells recovered and arthritis rapidly developed in a severe form. Intranasal PG treatment of recipient SCID mice was ineffective when cells from non-tolerized arthritic donors were transferred, in which case the regular weekly ‘tolerizing’ dose of PG made the disease worse. Our results suggest that mucosal treatment in an already existing disease may result in paradoxical outcomes.Keywords
This publication has 58 references indexed in Scilit:
- Control of rheumatoid arthritis by oral toleranceArthritis & Rheumatism, 2001
- Designing and Maintaining the Mature TCR RepertoireImmunity, 1999
- T-Cell Response to Orally Administered Antigens and Its Role in the Treatment of Antoimmune DiseasesPublished by S. Karger AG ,1998
- Oral Administration of the Immunodominant B-chain of Insulin Reduces Diabetes in a Co-transfer Model of Diabetes in the NOD Mouse and is Associated with a Switch from Th1 to Th2 CytokinesJournal of Autoimmunity, 1997
- Migration and homing of lymphocytes to lymphoid and synovial tissues in proteoglycan–induced murine arthritisArthritis & Rheumatism, 1994
- Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple SclerosisScience, 1993
- Mechanisms of self toleranceImmunology Today, 1992
- CD3+ T cells in severe combined immune deficiency (scid) mice. I. Transferred purified CD4+ T cells, but not CD8+ T cells are engrafted in the spleen of congenic scid miceEuropean Journal of Immunology, 1991
- Proteoglycan‐induced polyarthritis and spondylitis adoptively transferred to naive (nonimmunized) BALB/c miceArthritis & Rheumatism, 1990
- Peripheral T lymphocytes: expansion potential and homeostatic regulation of pool sizes and CD4/CD8 ratios in vivoEuropean Journal of Immunology, 1989